Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Blood

Volumn 101, Issue 2, 2003, Pages 425-432

  Marcucci, Guido ^a   Byrd, John C ^a   Dai, Guowei ^a   Klisovic, Marko I ^a   Kourlas, Peter J ^a   Young, Donn C ^a   Cataland, Spero R ^a   Fisher, Diane B ^a   Lucas, David ^a   Chan, Kenneth K ^a   Porcu, Pierluigi ^a   Lin, Zhong Pin ^a   Farag, Sherif F ^a   Frankel, Stanley R ^a   Zwiebel, James A ^a   Kraut, Eric H ^a   Balcerzak, Stanley P ^a   Bloomfield, Clara D ^a   Grever, Michael R ^a   Caligiuri, Michael A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUDARABINE; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DYSPNEA; ELECTROLYTE DISTURBANCE; FEMALE; FEVER; FLUID RETENTION; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; KIDNEY DISEASE; LIVER DISEASE; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RELAPSE; REMISSION; SEIZURE; SIDE EFFECT; THORAX PAIN; THROMBOCYTE COUNT; TUMOR CELL DESTRUCTION; VERTIGO; VOMITING;

EID: 0037438586     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1899     Document Type: Article

References (34)

1. Bloomfield C, Caligiuri M. Molecular biology of leukemia. In: De Vita V Jr, Hellman S, Rosenberg S, eds. Cancer: Principle and Practice of Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:2389-2404.
2. Caligiuri MA, Strout MP, Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol. 1997;24:32-44.
3. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
4. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer. 2001;92:1059-1073.
5. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 2001;13:463-469.
6. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-2953.
7. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 1997;34:9-19.
8. Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol. 1998;13:521-530.
9. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996;87:265-272.
10. Campos L, Rouault JP, Sabido O, et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
11. Banker DE, Radich J, Becker A, et al. The t(8;21) iranslocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res. 1998;4: 3051-3062.
12. Cotter FE. Antisense therapy of hematologic malignancies. Semin Hematol. 1999;36:9-14.
13. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 1994;84:595-600.
14. Cotter FE, Johnson P, Hall P, et al. Antisense oilgonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 1994;9:3049-3055.
15. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in Scid mice. Nat Med. 1998;4:232-243.
16. Kitada S, Miyashita T, Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against Bcl-2 RNAs. Antisense Res Dev. 1993;3:157-169.
17. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:1812-1823.
18. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 2000;356:1728-1733.
19. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
20. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia. 1998;12:1482-1489.
21. Estey E,Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671-678.
22. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A. Antisense oligodeoxyribonucleotide down-regulation of Bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther. 1995;2:207-212.
23. Warzocha K. Antisense strategy in hematological malignancies. Cytokines Cell Mol Ther. 1999;5: 15-23.
24. Gewirtz AM. Antisense oligonudeotide therapeutics for human leukemia. Curr Opin Hematol. 1998;5:59-71.
25. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res. 2002;8:679-683.
26. Chi KN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res. 2001;7:3920-3927.
27. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 2002;13:539-545.
28. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000; 95:3929-3938.
29. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia. 1994;8:1842-1846.
30. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. EurJ Haematol. 1996;56:308-312.
31. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73:265-271.
32. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58:105-109.
33. Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma. 1997;25:579-583.
34. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol. 2001;112:127-137.